Webinar Date/Time: Friday, May 19, 2023 at 11am EDT| 10am CDT | 8am PDT
In this Drug Digest video, our speakers will discuss early phase development in outsourcing and the role of CDMOs in the typical business model.
Register Free: https://www.pharmtech.com/pt_w/outsourcing-landscape
Event Overview
Contract research organization (CRO) services are continuing to grow at an immense pace, driven in part by rapidly evolving technologies used in drug discovery and development. According to market research, the CRO services sector is forecast to be worth $127.3 billion by 2028, representing a double digit (10.7%) compound annual growth rate (1).
As the bio/pharma industry gravitates towards more complex clinical pipelines, outsourcing has been a necessity for many as it can control costs/minimize internal staff and resources, for example, in addition to getting products out in the most efficient way (1,2). An area that is not highlighted as much in industry commentary is the early phase development of outsourcing and what needs to be improved to remain in line with the fast pace of change happening within this industry.
In this Drug Digest video, Chris Moreton, FinnBrit Consulting, will provide expert insights into what happens in early phase development and highlight the benefits and challenges of this step in the outsourcing process.
Key Learning Objectives:
Who Should Attend:
Speakers
Chris Moreton, PhD
FinnBrit Consulting
Christine Fürst
Senior Director
Key Account Management Europe
Register Free: https://www.pharmtech.com/pt_w/outsourcing-landscape
Sponsors
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.